Missouri Trust & Investment Company’s Novo Nordisk NVO Stock Holding History

Missouri Trust & Investment Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-800	Closed	-$29.4K	–	309
2026 Q1	$29.4K	Hold	800	–	–	0.01%	271
2025 Q4	$40.7K	Hold	800	–	–	0.01%	243
2025 Q3	$44.4K	Hold	800	–	–	0.01%	241
2025 Q2	$55.2K	Hold	800	–	–	0.02%	210
2025 Q1	$55.6K	Hold	800	–	–	0.02%	201
2024 Q4	$68.8K	Hold	800	–	–	0.02%	187
2024 Q3	$95.3K	Hold	800	–	–	0.03%	161
2024 Q2	$114K	Hold	800	–	–	0.04%	146
2024 Q1	$103K	Hold	800	–	–	0.04%	150
2023 Q4	$82.8K	Hold	800	–	–	0.03%	158
2023 Q3	$72.8K	Hold	800	–	–	0.03%	159
2023 Q2	$64.7K	Hold	800	–	–	0.04%	171
2023 Q1	$63.7K	Hold	800	–	–	0.04%	152
2022 Q4	$54K	Hold	800	–	–	0.03%	169
2022 Q3	$40K	Hold	800	–	–	0.03%	185
2022 Q2	$45K	Hold	800	–	–	0.03%	183
2022 Q1	$44K	Hold	800	–	–	0.03%	191
2021 Q4	$45K	Buy	+800	New	+$43.3K	0.03%	207

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Missouri Trust & Investment Company's NVO Position: Q2 2026 in Review

Missouri Trust & Investment Company sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 800 shares — an estimated $29.4K sold.

Missouri Trust & Investment Company first reported a position in NVO in Q4 2021 and held it in 18 quarters. The position peaked at $114K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Missouri Trust & Investment Company reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
Missouri Trust & Investment Company sold 800 Novo Nordisk shares in Q2 2026, an estimated $29.4K.
Missouri Trust & Investment Company first reported a position in Novo Nordisk in Q4 2021 and held it in 18 quarters.
Missouri Trust & Investment Company's Novo Nordisk position peaked at $114K in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Missouri Trust & Investment Company's 13F filing for Q2 2026, filed 13 Aug 2026.